Received Oct 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | — | — |
erythema, swelling and pain at the injection site; erythema, swelling and pain at the injection site; erythema, swelling and pain at the injection site; This spontaneous report was received regarding her mother, a 64-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 06-Oct-2025, the patient started therapy with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE), 0.5 mL (.5ML), (lot # and expiration date were not reported) for prophylaxis. On 06-Oct-2025, the patient experienced erythema, swelling and pain at the injection site after being administered Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE). At the reporting time, the outcome of erythema, swelling and pain at the injection site was unknown. The causal relationship between the events and Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) was not reported.